Divya Shan

2 months ago | onlinelibrary.wiley.com | Divya Shan |Marisa Riley |David M. Milgraum

1 Introduction Dupilumab, a monoclonal antibody targeting the interleukin-4 receptor alpha, has transformed the management of moderate-to-severe atopic dermatitis. While it offers substantial relief for many patients, emerging reports have identified an adverse effect not highlighted in initial clinical trials: erythematous eruptions on the head and neck [1].

May 8, 2024 | onlinelibrary.wiley.com | Divya Shan |NEHA GUPTA |Alex G. Ortega-Loayza |Sofia Shea

1 INTRODUCTION The hallmark feature of dermatomyositis (DM), an idiopathic inflammatory disorder, is symmetric proximal skeletal muscle weakness with characteristic cutaneous manifestations.1 Besides the pathognomonic findings of Gottron papules and heliotrope rash, other additional skin manifestations include facial erythema, shawl sign, poikiloderma, and calcinosis cutis.2 There can also be associated extramuscular manifestations, such as interstitial lung disease (ILD), myocarditis, and...